α-dystroglycanopathy

Translational Research in Muscular Dystrophy

Volumn , Issue , 2016, Pages 21-38

  Kanagawa, Motoi ^a   Toda, Tatsushi ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Dystroglycan; Fukutin; Fukuyama congenital muscular dystrophy; Gene therapy; Glycosylation; O Mannose

Indexed keywords

EID: 85018229512     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-4-431-55678-7_2     Document Type: Chapter

References (93)

1. Ervasti JM, Ohlendieck K, Kahl SD et al (1990) Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle. Nature 345: 315-319
2. Barresi R, Campbell KP (2006) Dystroglycan: from biosynthesis to pathogenesis of human disease. J Cell Sci 119: 199-207
3. Hara Y, Balci-Hayta B, Yoshida-Moriguchi T et al (2011) A dystroglycan mutation associated with limb-girdle muscular dystrophy. N Engl J Med 364: 939-946
4. Hayashi YK, Ogawa M, Tagawa K et al (2001) Selective deficiency of alpha-dystroglycan in Fukuyama-type congenital muscular dystrophy. Neurology 57: 115-121
5. Michele DE, Barresi R, Kanagawa M et al (2002) Post-translational disruption of dystroglycan-ligand interactions in congenital muscular dystrophies. Nature 418: 417-422
6. Brockington M, Blake DJ, Prandini P et al (2001) Mutations in the fukutin-related protein gene (FKRP) cause a form of congenital muscular dystrophy with secondary laminin alpha2 deficiency and abnormal glycosylation of alpha-dystroglycan. Am J Hum Genet 69: 1198-1209
7. Brockington M, Yuva Y, Prandini P et al (2001) Mutations in the fukutin-related protein gene (FKRP) identify limb girdle muscular dystrophy 2I as a milder allelic variant of congenital muscular dystrophy MDC1C. Hum Mol Genet 10: 2851-2859
8. Longman C, Brockington M, Torelli S et al (2003) Mutations in the human LARGE gene cause MDC1D, a novel form of congenital muscular dystrophy with severe mental retardation and abnormal glycosylation of alpha-dystroglycan. Hum Mol Genet 12: 2853-2861
9. Toda T, Kobayashi K, Takeda S et al (2003) Fukuyama-type congenital muscular dystrophy (FCMD) and alpha-dystroglycanopathy. Congenit Anom (Kyoto) 43: 97-104
10. Michele DE, Campbell KP (2003) Dystrophin-glycoprotein complex: post-translational processing and dystroglycan function. J Biol Chem 278: 15457-15460
11. Fukuyama Y, Osawa M, Suzuki H (1981) Congenital progressive muscular dystrophy of the Fukuyama type - clinical, genetic and pathological considerations. Brain Dev 3: 1-29
12. Toda T, Kobayashi K, Kondo-Iida E (2000) The Fukuyama congenital muscular dystrophy story. Neuromuscul Disord 10: 153-159
13. Kano H, Kobayashi K, Herrmann R (2002) Deficiency of alpha-dystroglycan in muscle-eyebrain disease. Biochem Biophys Res Commun 291: 1283-1286
14. Murakami T, Hayashi YK, Noguchi S et al (2006) Fukutin gene mutations cause dilated cardiomyopathy with minimal muscle weakness. Ann Neurol 60: 597-602
15. D’Amico A, Tessa A, Bruno C et al (2006) Expanding the clinical spectrum of POMT1 phenotype. Neurology 66: 1564-1567
16. Godfrey C, Clement E, Mein R et al (2007) Refining genotype phenotype correlations in muscular dystrophies with defective glycosylation of dystroglycan. Brain 130: 2725-2735
17. Godfrey C, Foley AR, Clement E et al (2011) Dystroglycanopathies: coming into focus. Curr Opin Genet Dev 21: 278-285
18. Ibraghimov-Beskrovnaya O, Ervasti JM, Leveille CJ et al (1992) Primary structure of dystrophin- associated glycoproteins linking dystrophin to the extracellular matrix. Nature 355: 696-702
19. Kanagawa M, Saito F, Kunz S et al (2004) Molecular recognition by LARGE is essential for expression of functional dystroglycan. Cell 117: 953-964
20. Hara Y, Kanagawa M, Kunz S et al (2011) Like-acetylglucosaminyltransferase (LARGE)- dependent modification of dystroglycan at Thr-317/319 is required for laminin binding and arenavirus infection. Proc Natl Acad Sci U S A 108: 17426-17431
21. Chiba A, Matsumura K, Yamada H et al (1997) Structures of sialylated O-linked oligosaccharides of bovine peripheral nerve alpha-dystroglycan. The role of a novel O-mannosyltype oligosaccharide in the binding of alpha-dystroglycan with laminin. J Biol Chem 272: 2156-2162
22. Inamori K, Endo T, Gu J et al (2004) N-Acetylglucosaminyltransferase IX acts on the GlcNAc beta 1,2-Man alpha 1-Ser/Thr moiety, forming a 2,6-branched structure in brain O-mannosyl glycan. J Biol Chem 279: 2337-2340
23. Yoshida-Moriguchi T, Yu L, Stalnaker SH et al (2010) O-mannosyl phosphorylation of alphadystroglycan is required for laminin binding. Science 327: 88-92
24. Inamori K, Yoshida-Moriguchi T, Hara Y et al (2012) Dystroglycan function requires xylosyland glucuronyltransferase activities of LARGE. Science 335: 93-96
25. Goddeeris MM, Wu B, Venzke D et al (2013) LARGE glycans on dystroglycan function as a tunable matrix scaffold to prevent dystrophy. Nature 503: 136-140
26. Barresi R, Michele DE, Kanagawa M et al (2004) LARGE can functionally bypass alphadystroglycan glycosylation defects in distinct congenital muscular dystrophies. Nat Med 10: 696-703
27. Beltrán-Valero de Bernabé D, Currier S, Steinbrecher A et al (2002) Mutations in the Omannosyltransferase gene POMT1 give rise to the severe neuronal migration disorder Walker-Warburg syndrome. Am J Hum Genet 71: 1033-1043
28. van Reeuwijk J, Janssen M, van den Elzen C (2005) POMT2 mutations cause alphadystroglycan hypoglycosylation and Walker-Warburg syndrome. J Med Genet 42: 907-912
29. Manya H, Chiba A, Yoshida A et al (2004) Demonstration of mammalian protein O-mannosyltransferase activity: coexpression of POMT1 and POMT2 required for enzymatic activity. Proc Natl Acad Sci U S A 101: 500-505
30. Yoshida A, Kobayashi K, Manya H et al (2001) Muscular dystrophy and neuronal migration disorder caused by mutations in a glycosyltransferase, POMGnT1. Dev Cell 1: 717-724
31. Combs AC, Ervasti JM (2005) Enhanced laminin binding by alpha-dystroglycan after enzymatic deglycosylation. Biochem J 390: 303-309
32. Kuga A, Kanagawa M, Sudo A et al (2012) Absence of post-phosphoryl modification in dystroglycanopathy mouse models and wild-type tissues expressing non-laminin binding form of α-dystroglycan. J Biol Chem 287: 9560-9567
33. Manzini MC, Tambunan DE, Hill RS et al (2012) Exome sequencing and functional validation in zebrafish identify GTDC2 mutations as a cause of Walker-Warburg syndrome. Am J Hum Genet 91: 541-547
34. Stevens E, Carss KJ, Cirak S et al (2013) Mutations in B3GALNT2 cause congenital muscular dystrophy and hypoglycosylation of α-dystroglycan. Am J Hum Genet 92: 354-365
35. Jae LT, Raaben M, Riemersma M et al (2013) Deciphering the glycosylome of dystroglycanopathies using haploid screens for lassa virus entry. Science 340: 479-483
36. Yoshida-Moriguchi T, Willer T, Anderson ME et al (2013) SGK196 is a glycosylation-specific O-mannose kinase required for dystroglycan function. Science 341: 896-899
37. Peyrard M, Seroussi E, Sandberg-Nordqvist AC et al (1999) The human LARGE gene from 22q12.3-q13.1 is a new, distinct member of the glycosyltransferase gene family. Proc Natl Acad Sci U S A 96: 598-603
38. Grewal PK, Holzfeind PJ, Bittner RE et al (2001) Mutant glycosyltransferase and altered glycosylation of alpha-dystroglycan in the myodystrophy mouse. Nat Genet 28: 151-154
39. Buysse K, Riemersma M, Powell G et al (2013) Missense mutations in β-1,3-N-acetylglucosaminyltransferase 1 (B3GNT1) cause Walker-Warburg syndrome. Hum Mol Genet 22: 1746-1754
40. Bao X, Kobayashi M, Hatakeyama S et al (2009) Tumor suppressor function of lamininbinding alpha-dystroglycan requires a distinct beta3-N-acetylglucosaminyltransferase. Proc Natl Acad Sci U S A 106: 12109-12114
41. Willer T, Inamori KI, Venzke D et al (2014) The glucuronyltransferase B4GAT1 is required for initiation of LARGE-mediated α-dystroglycan functional glycosylation. Elife (in press). doi: 10.7554/eLife.03941
42. Praissman JL, Live DH, Wang S et al (2014) B4GAT1 is the priming enzyme for the LARGEdependent functional glycosylation of α-dystroglycan. Elife (in press). doi: 10.7554/eLife.03943
43. Kobayashi K, Nakahori Y, Miyake M et al (1998) An ancient retrotransposal insertion causes Fukuyama-type congenital muscular dystrophy. Nature 394: 388-392
44. Tachikawa M, Kanagawa M, Yu CC et al (2012) Mislocalization of fukutin protein by diseasecausing missense mutations can be rescued with treatments directed at folding amelioration. J Biol Chem 287: 8398-8406
45. Aravind L, Koonin EV (1999) The fukutin protein family - predicted enzymes modifying cellsurface molecules. Curr Biol 9: R836-R837
46. Kuchta K, Knizewski L, Wyrwicz LS et al (2009) Comprehensive classification of nucleotidyltransferase fold proteins: identification of novel families and their representatives in human. Nucleic Acids Res 37: 7701-7714
47. Vuillaumier-Barrot S, Bouchet-Séraphin C, Chelbi M et al (2012) Identification of mutations in TMEM5 and ISPD as a cause of severe cobblestone lissencephaly. Am J Hum Genet 91: 1135-1143
48. Roscioli T, Kamsteeg EJ, Buysse K et al (2012) Mutations in ISPD cause Walker-Warburg syndrome and defective glycosylation of α-dystroglycan. Nat Genet 44: 581-585
49. Willer T, Lee H, Lommel M et al (2012) ISPD loss-of-function mutations disrupt dystroglycan O-mannosylation and cause Walker-Warburg syndrome. Nat Genet 44: 575-580
50. Yang AC, Ng BG, Moore SA et al (2013) Congenital disorder of glycosylation due to DPM1 mutations presenting with dystroglycanopathy-type congenital muscular dystrophy. Mol Genet Metab 110: 345-351
51. Barone R, Aiello C, Race V et al (2012) DPM2-CDG: a muscular dystrophy-dystroglycanopathy syndrome with severe epilepsy. Ann Neurol 72: 550-558
52. Lefeber DJ, Schönberger J, Morava E et al (2009) Deficiency of Dol-P-Man synthase subunit DPM3 bridges the congenital disorders of glycosylation with the dystroglycanopathies. Am J Hum Genet 85: 76-86
53. Lefeber DJ, de Brouwer AP, Morava E et al (2011) Autosomal recessive dilated cardiomyopathy due to DOLK mutations results from abnormal dystroglycan O-mannosylation. PLoS Genet 7, e1002427
54. Carss KJ, Stevens E, Foley AR et al (2013) Mutations in GDP-mannose pyrophosphorylase B cause congenital and limb-girdle muscular dystrophies associated with hypoglycosylation of α-dystroglycan. Am J Hum Genet 93: 29-41
55. Ervasti JM, Campbell KP (1993) A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin. J Cell Biol 122: 809-823
56. Talts JF, Andac Z, Göhring W et al (1999) Binding of the G domains of laminin alpha1 and alpha2 chains and perlecan to heparin, sulfatides, alpha-dystroglycan and several extracellular matrix proteins. EMBO J 18: 863-870
57. Ido H, Harada K, Futaki S et al (2004) Molecular dissection of the alpha-dystroglycan- and integrin-binding sites within the globular domain of human laminin-10. J Biol Chem 279: 10946-10954
58. Yoon JH, Chandrasekharan K, Xu R et al (2009) The synaptic CT carbohydrate modulates binding and expression of extracellular matrix proteins in skeletal muscle: partial dependence on utrophin. Mol Cell Neurosci 41: 448-463
59. Gee SH, Montanaro F, Lindenbaum MH et al (1994) Dystroglycan-alpha, a dystrophinassociated glycoprotein, is a functional agrin receptor. Cell 77: 675-686
60. Bowe MA, Deyst KA, Leszyk JD et al (1994) Identification and purification of an agrin receptor from Torpedo postsynaptic membranes: a heteromeric complex related to the dystroglycans. Neuron 12: 1173-1180
61. Peng HB, Ali AA, Daggett DF et al (1998) The relationship between perlecan and dystroglycan and its implication in the formation of the neuromuscular junction. Cell Adhes Commun 5: 475-489
62. Sugita S, Saito F, Tang J et al (2001) A stoichiometric complex of neurexins and dystroglycan in brain. J Cell Biol 154: 435-445
63. Sato S, Omori Y, Katoh K et al (2008) Pikachurin, a dystroglycan ligand, is essential for photoreceptor ribbon synapse formation. Nat Neurosci 11: 923-931
64. Wright KM, Lyon KA, Leung H et al (2012) Dystroglycan organizes axon guidance cue localization and axonal pathfinding. Neuron 76: 931-944
65. Yurchenco PD (2011) Basement membranes: cell scaffoldings and signaling platforms. Cold Spring Harb Perspect Biol 3: a004911
66. Singhal N, Martin PT (2011) Role of extracellular matrix proteins and their receptors in the development of the vertebrate neuromuscular junction. Dev Neurobiol 71: 982-1005
67. Zaccaria ML, Di Tommaso F, Brancaccio A et al (2001) Dystroglycan distribution in adult mouse brain: a light and electron microscopy study. Neuroscience 104: 311-324
68. Kanagawa M, Omori Y, Sato S et al (2010) Post-translational maturation of dystroglycan is necessary for pikachurin binding and ribbon synaptic localization. J Biol Chem 285: 31208-31216
69. Willer T, Prados B, Falcón-Pérez JM et al (2004) Targeted disruption of the Walker-Warburg syndrome gene Pomt1 in mouse results in embryonic lethality. Proc Natl Acad Sci U S A 101: 14126-14131
70. Kurahashi H, Taniguchi M, Meno C et al (2005) Basement membrane fragility underlies embryonic lethality in fukutin-null mice. Neurobiol Dis 19: 208-217
71. Yagi H, Nakagawa N, Saito T et al (2013) AGO61-dependent GlcNAc modification primes the formation of functional glycans on α-dystroglycan. Sci Rep 3: 3288
72. Liu J, Ball SL, Yang Y et al (2006) A genetic model for muscle-eye-brain disease in mice lacking protein O-mannose 1,2-N-acetylglucosaminyltransferase (POMGnT1). Mech Dev 123: 228-240
73. Miyagoe-Suzuki Y, Masubuchi N, Miyamoto K et al (2009) Reduced proliferative activity of primary POMGnT1-null myoblasts in vitro. Mech Dev 126: 107-116
74. Takeda S, Kondo M, Sasaki J et al (2003) Fukutin is required for maintenance of muscle integrity, cortical histiogenesis and normal eye development. Hum Mol Genet 12: 1449-1459
75. Kanagawa M, Nishimoto A, Chiyonobu T et al (2009) Residual laminin-binding activity and enhanced dystroglycan glycosylation by LARGE in novel model mice to dystroglycanopathy. Hum Mol Genet 18: 621-631
76. Beedle AM, Turner AJ, Saito Y et al (2012) Mouse fukutin deletion impairs dystroglycan processing and recapitulates muscular dystrophy. J Clin Invest 122: 3330-3342
77. Kanagawa M, Yu CC, Ito C et al (2013) Impaired viability of muscle precursor cells in muscular dystrophy with glycosylation defects and amelioration of its severe phenotype by limited gene expression. Hum Mol Genet 22: 3003-3015
78. Chan YM, Keramaris-Vrantsis E, Lidov HG et al (2010) Fukutin-related protein is essential for mouse muscle, brain and eye development and mutation recapitulates the wide clinical spectrums of dystroglycanopathies. Hum Mol Genet 19: 3995-4006
79. Ackroyd MR, Skordis L, Kaluarachchi M et al (2009) Reduced expression of fukutin related protein in mice results in a model for fukutin related protein associated muscular dystrophies. Brain 132: 439-451
80. Hu H, Li J, Gagen CS et al (2011) Conditional knockout of protein O-mannosyltransferase 2 reveals tissue-specific roles of O-mannosyl glycosylation in brain development. J Comp Neurol 519: 1320-1337
81. Holzfeind PJ, Grewal PK, Reitsamer HA et al (2002) Skeletal, cardiac and tongue muscle pathology, defective retinal transmission, and neuronal migration defects in the Large (myd) mouse defines a natural model for glycosylation-deficient muscle-eye-brain disorders. Hum Mol Genet 11: 2673-2687
82. Han R, Kanagawa M, Yoshida-Moriguchi T et al (2009) Basal lamina strengthens cell membrane integrity via the laminin G domain-binding motif of alpha-dystroglycan. Proc Natl Acad Sci U S A 106: 12573-12579
83. Taniguchi M, Kurahashi H, Noguchi S et al (2006) Aberrant neuromuscular junctions and delayed terminal muscle fiber maturation in alpha-dystroglycanopathies. Hum Mol Genet 15: 1279-1289
84. Nakano I, FunahashiM, Takada K et al (1996) Are breaches in the glia limitans the primary cause of the micropolygyria in Fukuyama-type congenital muscular dystrophy (FCMD)? Pathological study of the cerebral cortex of an FCMD fetus. Acta Neuropathol 91: 313-321
85. Moore SA, Saito F, Chen J et al (2002) Deletion of brain dystroglycan recapitulates aspects of congenital muscular dystrophy. Nature 418: 422-425
86. Myshrall TD, Moore SA, Ostendorf AP et al (2012) Dystroglycan on radial glia end feet is required for pial basement membrane integrity and columnar organization of the developing cerebral cortex. J Neuropathol Exp Neurol 71: 1047-1063
87. Satz JS, Ostendorf AP, Hou S et al (2010) Distinct functions of glial and neuronal dystroglycan in the developing and adult mouse brain. J Neurosci 30: 14560-14572
88. Yu M, He Y, Wang K et al (2013) Adeno-associated viral-mediated LARGE gene therapy rescues the muscular dystrophic phenotype in mouse models of dystroglycanopathy. Hum Gene Ther 24: 317-330
89. Xu L, Lu PJ, Wang CH et al (2013) Adeno-associated virus 9 mediated FKRP gene therapy restores functional glycosylation of α-dystroglycan and improves muscle functions. Mol Ther 21: 1832-1840
90. Vannoy CH, Xu L, Keramaris E et al (2014) Adeno-associated virus-mediated overexpression of LARGE rescues α-dystroglycan function in dystrophic mice with mutations in the fukutinrelated protein. Hum Gene Ther Methods 25: 187-196
91. Whitmore C, Fernandez-Fuente M, Booler H et al (2014) The transgenic expression of LARGE exacerbates the muscle phenotype of dystroglycanopathy mice. Hum Mol Genet 23: 1842-1855
92. Saito F, Kanagawa M, Ikeda M et al (2014) Overexpression of LARGE suppresses muscle regeneration via down-regulation of insulin-like growth factor 1 and aggravates muscular dystrophy in mice. Hum Mol Genet 23: 4543-4558
93. Taniguchi-Ikeda M, Kobayashi K, Kanagawa M et al (2011) Pathogenic exon-trapping by SVA retrotransposon and rescue in Fukuyama muscular dystrophy. Nature 478: 127-131